Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Newly Diagnosed Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Testing effectiveness (Phase 2)UnknownNCT00526734
What this trial is testing

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Erasme University Hospital 100
Testing effectiveness (Phase 2)Study completedNCT02874742
What this trial is testing

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 224
Large-scale testing (Phase 3)UnknownNCT00546988
What this trial is testing

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

Who this might be right for
Multiple Myeloma
University of Wuerzburg 600
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Testing effectiveness (Phase 2)Looking for participantsNCT05828511
What this trial is testing

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

Who this might be right for
Multiple Myeloma
Regeneron Pharmaceuticals 149
Very early researchLooking for participantsNCT06407947
What this trial is testing

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02237261
What this trial is testing

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

Who this might be right for
Multiple Myeloma
University Hospital Heidelberg 46
Large-scale testing (Phase 3)Study completedNCT01091831
What this trial is testing

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 389
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07600151
What this trial is testing

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
Myeloma MultipleMyeloma
Universitätsklinikum Hamburg-Eppendorf 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT04653246
What this trial is testing

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Autologous Stem Cell Transplant
Jacob Laubach, MD 52
Testing effectiveness (Phase 2)UnknownNCT03641456
What this trial is testing

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Who this might be right for
MyelomaNewly DiagnosedHigh Risk
Sun Yat-sen University 50
Testing effectiveness (Phase 2)Study completedNCT02649790
What this trial is testing

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Karyopharm Therapeutics Inc 277
Not applicableStudy completedNCT01809717
What this trial is testing

Multiple Myeloma and Exercise

Who this might be right for
Newly Diagnosed Multiple Myeloma
Abramson Cancer Center at Penn Medicine 10
Large-scale testing (Phase 3)Study completedNCT00551928
What this trial is testing

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaNewly Diagnosed Patients
Fondazione EMN Italy Onlus 402